P084 - Application of Raman spectroscopy coupled with chemometrics to the early diagnostics and classification of prostate cancer

Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): A. Sanchis-Bonet, C.A. Menor Galvan, E. Garcia Rico, D. Roman Curto, M. Sanchez Chapado, A. Bajo-Chueca
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research

Related Links:

Condition:   Prostate Cancer Interventions:   Drug: Niraparib;   Drug: Leuprolide;   Drug: Abiraterone Acetate;   Radiation: Stereotactic body radiotherapy (SBRT) Sponsors:   University of Michigan Rogel Cancer Center;   Janssen Scientific Affairs, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Short-term exercise may help reduce the adverse side effects of hormone therapy for patients with prostate cancer, according to a study published in theBritish Journal of Urology International (BJUI).Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
Authors: Chen YF, Liang YX, Yang JA, Yuan DZ, Li J, Zheng SS, Wan YP, Wang B, Han ZD, Zhong WD Abstract Abnormal expression of Holliday junction recognition protein (HJURP) in several types of tumor cells plays a vital role in the formation and progression of tumors. Few studies have investigated the role of HJURP in prostate cancer (PCa). The aim of this study was to analyze the expression levels of HJURP in PCa and to establish the association with clinicopathological data. Reverse transcription quantitative polymerase chain reaction and immunohistochemical analysis were used to detect the expression levels of HJ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies. PMID: 31815592 [PubMed - in process]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Source: IEEE/ACM Transactions on Computational Biology and Bioinformatics - Category: Bioinformatics Source Type: research
Prostate Cancer and Prostatic Diseases, Published online: 11 December 2019; doi:10.1038/s41391-019-0196-4Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
Publication date: Available online 9 December 2019Source: Reports of Practical Oncology &RadiotherapyAuthor(s): A. Zapatero, M. Adrados, L. Torres, M.S. Talaya, A. Cruz Conde, C. Martin de Vidales, L. Vega Piris, C. Olivier, M.T. MurilloABSTRACTBackground/aim(s)To determine the impact of post-treatment biopsy results on 10-year metastasis-free survival (MFS), overall survival (OS) and cause-specific survival (CSS) in localized prostate cancer (PCa) patients treated with high-dose radiotherapy (RT).Materials/MethodsRetrospective analysis of 232 patients with T1c-T3bN0M0 PCa who underwent a prostate biopsy 24–36 mo...
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Conclusion: Our results were not able to show any significant correlation between increasing convenience with QUANTEC limits and lower rectal toxicity. Conclusively, new dosimetric definitions are warranted to predict acute rectal toxicity more accurately in prostate cancer patients during IMRT treatment.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Noncanonical Wnt as a prognostic marker in prostate cancer: "You can't always get what you Wnt". Expert Rev Mol Diagn. 2019 Dec 07;: Authors: Fisher RR, Pleskow HM, Bedingfield K, Miyamoto DT Abstract Introduction: Wnt signaling is important for normal development, cell proliferation, and cell differentiation. However, aberrations in the pathway can lead to tumorigenesis and cancer progression. Recent genome-wide studies have demonstrated the frequent occurrence of Wnt pathway alterations in prostate cancer. Although alterations in the canonical Wnt pathway in prostate cancer may have an impa...
Source: Expert Review of Molecular Diagnostics - Category: Laboratory Medicine Tags: Expert Rev Mol Diagn Source Type: research
More News: Cancer | Cancer & Oncology | Men | Prostate Cancer | Urology & Nephrology